Fifth S-1/A keeps the 16.25 million share Nasdaq deal in motion
A fifth amendment means MED-X is still reworking terms on a Nasdaq listing that would float 16.25 million shares, with Maxim Group running the book. Pricing terms remain unset, so the dilution math is the only number investors can anchor to right now.
Source: SEC filing

